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Background
Sublingual immunotherapy (SLIT) has been regarded as
a viable alternative to subcutaneous immunotherapy
(SCIT) since its introduction in 1986. Several studies
have demonstrated the efficacy of SLIT. The safety
profile of SLIT is superior to that of SCIT. No fatalities
have been reported, and severe systemic reactions are
rare. The rate of adverse event (AE) after SLIT is variable
in the reported studies, but local AEs are predominant.
Systemic side effects such as rhinitis, asthma, urticaria,
angioedema, and hypotension make up a minority of the
adverse reactions because local reactions (oropharyngeal
or gastrointestinal) are most frequently reported.
Objectives
To determine the efficacy and safety of SLIT in allergic
rhinitis patients treated in our clinic.
Methods
This is a descriptive, observational an retrospective
study that included all the records files of private prac-
tice patients during the last 2 years with allergic rhinitis
sensitized to aeroallergens (mites, grass and weeds pollen)
confirmed by positive skin prick test, to which SLIT was
initiated by a daily scheme in maintenance doses and then
all of the patients being evaluated monthly searching for
adverse reactions.
Results
A total of 20 patients were included, with ages from 4 to
35 years (average of 12.3 years), 11 (55%) females and
9 (45%) males, from which 17 (85%) were children’s and 3
(15%) adults, all with the diagnose of allergic rhinitis, the
average time with SLIT was 21 months (+/- 9.4) finding
important clinical improvement in all patients from the
symptoms of allergic rhinitis. No adverse reaction was
found, neither systemic or local at any time. All patients
stick to their treatment with a complete scheme of SLIT.
Conclusions
SLIT demonstrated to be a secure and efficient in this
group of patients, both pediatric and adults with allergic
rhinitis with nonadverse reactions and with significant
clinical improvement.
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